First-ever treatment in multiple sclerosis.

Details

Serval ID
serval:BIB_C4E341AFF275
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
First-ever treatment in multiple sclerosis.
Journal
Revue neurologique
Author(s)
Pantazou V., Pot C., Du Pasquier R., Le Goff G., Théaudin M.
ISSN
0035-3787 (Print)
ISSN-L
0035-3787
Publication state
In Press
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
The current treated MS population is very different from that of patients in randomized clinical trials.
To study the long-term efficacy and tolerance of fingolimod (FTY) and dimethyl fumarate (DMF), both available as first-line treatment in early-treated treatment-naïve MS patients.
Retrospective analysis of 75 patients from our prospective MS registry fulfilling the inclusion criteria: FTY or DMF as first-line treatment, treatment initiation within 36months of disease onset and treatment duration>12months.
Demographics and MRI characteristics at baseline were similar in both groups (FTY 55 patients, DMF 20), but patients on FTY had higher pretreatment clinical activity (P=0.008). Twenty-two percent of patients in the FTY group and 15% in the DMF group had highly active disease. At last follow-up (mean: 44.2, SD: 17.3months), the majority of the patients were still on treatment while 54.5% of FTY and 65% of DMF patients reached NEDA 3 status (P=0.444). Both treatments significantly decreased relapses and occurrence of new T1 Gd-enhancing lesions (P<0.001). The main reason for discontinuation was disease activity without severe side effects on either treatment.
Our findings support efficacy and tolerance of both drugs in early-treated treatment-naive MS patients, arguing in favour of efficient early immunomodulation in MS patients. Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity.
Keywords
Dimethyl fumarate, Disease modifying treatment, Fingolimod, Multiple sclerosis, Real-world study
Pubmed
Create date
17/08/2020 9:44
Last modification date
02/09/2020 5:22
Usage data